Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
27.37
+0.66 (2.47%)
Mar 4, 2026, 10:24 AM EST - Market open
Immunovant Market Cap
Immunovant has a market cap or net worth of $5.57 billion as of March 4, 2026. Its market cap has increased by 61.32% in one year.
Market Cap
5.57B
Enterprise Value
4.44B
1-Year Change
61.32%
Ranking
Category
Stock Price
$27.37
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $5.57B, an increase of 4,378.94%. That is a compound annual growth rate of 76.32%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 3, 2026 | 5.44B | 5.52% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Belite Bio | 6.30B |
| Rhythm Pharmaceuticals | 6.12B |
| Cogent Biosciences | 6.00B |
| Protagonist Therapeutics | 5.83B |
| CRISPR Therapeutics AG | 5.57B |
| Caris Life Sciences | 5.48B |
| PTC Therapeutics | 5.33B |
| Mirum Pharmaceuticals | 5.30B |